F2G is a world-leading UK and Austrian based biotech company, focused on the discovery and development of novel therapies to treat life threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides, active against Aspergillus and other rare and resistant moulds, that act via a completely different mechanism than currently marketed agents. The company has a seasoned management team and Board and is backed by experienced, high-quality venture investors.
A Phase IIb open label study with the lead candidate, olorofim, is currently underway with sites in 6 countries across Europe, the USA and Australia. This study is recruiting patients with invasive aspergillosis, scedosporiosis and other rare and resistant mould infections, who are poorly-responsive to, resistant to or intolerant of currently-approved antifungal agents. Olorofim is being developed both as IV and oral formulations, for the treatment of adults and children with invasive mould infections.